Viewing Study NCT00251433


Ignite Creation Date: 2025-12-25 @ 2:50 AM
Ignite Modification Date: 2026-01-08 @ 10:00 PM
Study NCT ID: NCT00251433
Status: TERMINATED
Last Update Posted: 2023-03-31
First Post: 2005-11-08
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: GW572016 With Docetaxel and Trastuzumab for the Treatment Of Untreated ErbB2 Over-Expressing Metastatic Breast Cancer
Sponsor: Novartis Pharmaceuticals
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module References Module